Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance

BACKGROUND: Tolvaptan is a vasopressin type 2 receptor antagonist and has been used to treat autosomal dominant polycystic kidney disease (ADPKD) since 2014. There has been limited real-world data on the safety and efficacy of tolvaptan. METHODS: This post-marketing surveillance was conducted to eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Mochizuki, Toshio, Muto, Satoru, Miyake, Masateru, Tanaka, Toshiki, Wang, Wenchyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460520/
https://www.ncbi.nlm.nih.gov/pubmed/34228250
http://dx.doi.org/10.1007/s10157-021-02100-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460520/
https://www.ncbi.nlm.nih.gov/pubmed/34228250
http://dx.doi.org/10.1007/s10157-021-02100-0

Ejemplares similares